Navigation Links
PARI Granted US Patent for Vortex Holding Chamber
Date:7/21/2009

MIDLOTHIAN, Va., July 21 /PRNewswire/ -- Today, PARI Respiratory Equipment was granted a US Patent for its Vortex Holding Chamber, a unique, non-electrostatic, holding chamber with a one piece, dual-valve system that optimizes patient inhalation and exhalation for more efficient medication delivery with a metered dose inhaler (MDI).

"While metered dose inhalers offer a quick burst of medication, there are a number of problems delivering an effective dose to patients. These include medication waste due to high-speed delivery to the back of the throat and loss of medication due to improper use. The Vortex Holding Chamber does a wonderful job of addressing these issues, in particular for young patients and for any person who has difficulty using an inhaler, by allowing patients to breathe normally while using the one piece, dual-valve system to direct medication flow and a patient's exhalation breaths," said Dr. Welch, co-director of the Allergy and Asthma Medical Group and Research Center in San Diego, and clinical professor at the University of California, San Diego School of Medicine.

"Innovations like the Vortex Holding Chamber truly enhance respiratory care by making therapies easier for patients. We are very pleased that the Vortex Holding Chamber has been granted this US patent, because the Vortex Holding Chamber ensures patients do not have to worry about coordinating their breaths when using a MDI to get an effective treatment. This enhances drug delivery, minimizes drug delivered to the throat, and allows low resistance inhalation and exhalation with the device," added Geoff A. Hunziker, president of PARI Respiratory Equipment.

The Vortex Holding Chamber has a number of unique features. When a patient inhales, the Vortex Holding Chamber directs airflow through a medication holding chamber and into the patient. During exhalation, airflow is directed out of the device while reducing medication loss. Because it is metal, the Vortex Holding Chamber's non-electrostatic walls do not attract medication as plastic devices do, thereby reducing medication loss in the holding chamber. It also features a cyclonic, inspiratory flow pattern that further enhances aerosol delivery. Patients can breathe normally while the Vortex Holding Chamber's one piece, dual-valve system enhances medication delivery and reduce drug waste.

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. Its Vortex Holding Chamber's anti-static, valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at www.Pari.com

Additional information is available by contacting Kirsten Ayars at 805-845-5682 or Ashley Weigand at 804-253-7274 x711.


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
3. USC granted $8.4 million for autism research
4. Aida Granted Additional Anti-Cancer Patent
5. CME LLC Granted Five-Year Full Approval by the American Psychological Association
6. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
7. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
10. Phylonix granted broad European patent for transplanting human cells into zebrafish
11. Seven Community Service Organizations Granted Over $60,000 From Delta Dental Of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... MD (PRWEB) , ... July 27, 2017 , ... ... Teams of entrepreneurs will compete to form startup companies around 117 breakthrough inventions ... Heart, Lung, and Blood Institute, and National Institute of Biomedical Imaging and Bioengineering), ...
(Date:7/27/2017)... ... July 27, 2017 , ... Cremations recently surpassed traditional burials ... Association, this trend is expected to continue with over 70% of Americans projected to ... demand for new innovations that enable families to celebrate the life of a lost ...
(Date:7/26/2017)... ... 2017 , ... An inventor from Salisbury, N.C., knows the difficulties involved with ... and dignified way to keep leeches in place during therapy," she said. "That’s why ... an effective way to keep a leech in place on the skin during therapy. ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... Management Solutions as part of their continued efforts to provide innovative offerings to ... the best IT resources and build dynamic, high-performing teams to address healthcare IT’s ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
Breaking Medicine Technology: